La Rochelle, September 15, 2023 – Valbiotis (FR0013254851 – ALVAL, PEA / PME eligible), a Research and Development company with a commercial dimension, committed to scientific innovation, for the prevention and fight against metabolic and cardiovascular diseases, invites individual shareholders to an exchange with its managers during a Web conference moderated by Aldo SICURANI, General Delegate of the F2IC.
The opportunity for Sébastien PELTIER, Co-founder and Chairman of the Executive Committee of the Company, and Pascal SIRVENT, Scientific Director, to look back on the decisive milestone reached with the remarkable results of the Phase II/III clinical study on TOTUM• 63, as well as on the next strategic steps.
Investors can ask them their questions now by email at [email protected], or live during the Web conference on September 20 at 6:00 p.m. (opening from 5:55 p.m.).
To register or log in: https://channel.royalcast.com/f2ic/#!/f2ic/20230920_1